Compare KLIC & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLIC | ICUI |
|---|---|---|
| Founded | 1951 | 1984 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.6B |
| IPO Year | 2004 | 1995 |
| Metric | KLIC | ICUI |
|---|---|---|
| Price | $84.50 | $175.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $54.67 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 913.3K | 294.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 100.32 | ★ 100.62 |
| EPS | ★ 2.06 | 1.96 |
| Revenue | $654,081,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $45.81 | N/A |
| Revenue Next Year | $11.35 | $4.46 |
| P/E Ratio | ★ $41.10 | $89.34 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.02 | $112.50 |
| 52 Week High | $135.80 | $192.85 |
| Indicator | KLIC | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 50.93 |
| Support Level | $81.97 | $138.91 |
| Resistance Level | $89.59 | $191.07 |
| Average True Range (ATR) | 3.91 | 3.93 |
| MACD | -0.26 | -1.52 |
| Stochastic Oscillator | 11.41 | 1.53 |
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.